Akili, Inc. (AKLI)

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who.

NEW ORLEANS , June 14, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options.

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating: Akili, Inc. (NASDAQ: AKLI ), relating to a tender offer from Vital Therapeutics Corporation.

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options.

NEW ORLEANS, LA / ACCESSWIRE / June 5, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Akili , Inc. ( NASDAQ: AKLI ), relating to a tender offer from Vital Therapeutics Corporation. Under the terms of the agreement, Vital Therapeutics Corporation will acquire all the outstanding shares of Akili common stock for $0.4340 cash per share.

NEW YORK , June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Akili, Inc. (NASDAQ: AKLI), relating to a tender offer from Vital Therapeutics Corporation.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akili, Inc. (NASDAQ: AKLI) to Virtual Therapeutics for $0.4340 per share of common stock in cash is fair to Akili shareholders. Halper Sadeh encourages Akili shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Akil.

MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics. Click here to learn how to join the https://www.ademilaw.com/case/akili-inc or call Guri Ademi toll-free at 866-264-3995.

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.

KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)--Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced the signing of a definitive merger agreement to form a diversified, leading digital health company. Under the terms of the agreement, Akili shareholders will receive $0.4340 per share of common stock in cash. The per share purchase price represents an approxi.

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company's board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder value. “We are working expeditiously with our board of directors and our external advisors and look forwar.

Akili (NASDAQ: AKLI ) stock is rocketing higher on Tuesday after the digital medicine company provided investors with a positive corporate update. According to this update, Shionogi has canceled and forgiven $5 million in debt that Akili owed it.

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an update on business progress. “We continue to see clear demand for our innovative, digital therapeutics, particularly amidst the ongoing mental health crisis and increasing awareness of adult ADHD prevalence,” said Matt Franklin, Chief Executive Officer at Akili. “Our mid-year shift to a leaner, custom.